SUBSCRIBE
SUBSCRIBE

Panbela Therapeutics Inc.

IN THE PRESS
Business
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
October 31, 2022
 · 
6 min read
BioMidwest
Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference
October 6, 2022
 · 
6 min read
Deals
Panbela Announces Pricing of Approximately $6 Million Public Offering
September 30, 2022
 · 
7 min read
Policy
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
September 29, 2022
 · 
7 min read
Business
Panbela Provides Business Update and Reports Q2 2022 Financial Results
August 15, 2022
 · 
13 min read
BioMidwest
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal AdenocarcinomaExpects interim data by early 2024
August 11, 2022
 · 
7 min read
BioMidwest
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 4, 2022
 · 
6 min read
Business
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results
August 1, 2022
 · 
6 min read
Drug Development
Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic
June 28, 2022
 · 
7 min read
Deals
Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.
June 16, 2022
 · 
6 min read
Load More
JOBS